24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion

Trial Profile

24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Acamprosate/baclofen (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PLEODIAL-II
  • Sponsors Pharnext
  • Most Recent Events

    • 13 Dec 2016 Results published in the Pharnext Media Release.
    • 13 Dec 2016 According to a Pharnext media release, data from PLEODIAL clinical trial (this study and CTP 253068) presented at the 9th Clinical Trials on Alzheime's Disease (CTAD) conference.
    • 01 Dec 2016 According to a Pharnext media release, data from this study will be presented at the 9th Clinical Trials on Alzheimers Disease (CTAD) conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top